Parkinson's Disease Trial, Recruiting NCT07145190 Sponsor: Bial - Portela C S.A. Condition: Parkinson's Disease
Back to Parkinsons Disease

Parkinson's Disease Trial, Recruiting

NCT07145190
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are 18 years of age or older.
  • People who have been clinically diagnosed with idiopathic Parkinson's disease (Parkinson's disease with no known external cause).
  • People for whom a doctor is planning to start treatment with sublingual apomorphine (a medication placed under the tongue) for "OFF episodes" — periods when Parkinson's symptoms return or worsen between doses of regular medication.
  • People who have not yet started the dose-adjustment or ongoing maintenance phase of sublingual apomorphine treatment.
  • People who have given written consent to take part in the study.

Who may not be able to join:

  • People who are currently taking part in another clinical trial involving an experimental drug.
  • People who have been assessed by the investigator as having dementia or signs of cognitive (thinking or memory) decline.
  • People who have a history of a psychotic disorder (a condition involving a loss of contact with reality, such as hallucinations or delusions).
  • People who have any other medical reason that would make sublingual apomorphine unsuitable for them, as outlined in the medication's official prescribing guidelines (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Jan Kassubek, Prof Dr med, Praxis für Neurologie und Geriatrie (Ulm)

Phone: +351229866100

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Bial - Portela C S.A.
Registry
ClinicalTrials.gov
Start date
27 August 2025
Est. completion
1 February 2028

Where this trial is recruiting

🇩🇪 Germany

Primary endpoints

Identify the most frequent dose used after dose-adjustment

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov